Header Logo

Connection

Paul Thompson to Enzyme Inhibitors

This is a "connection" page, showing publications Paul Thompson has written about Enzyme Inhibitors.
Connection Strength

7.421
  1. Mondal S, Gong X, Zhang X, Salinger AJ, Zheng L, Sen S, Weerapana E, Zhang X, Thompson PR. Halogen Bonding Increases the Potency and Isozyme Selectivity of Protein Arginine Deiminase 1 Inhibitors. Angew Chem Int Ed Engl. 2019 09 02; 58(36):12476-12480.
    View in: PubMed
    Score: 0.544
  2. Muth A, Subramanian V, Beaumont E, Nagar M, Kerry P, McEwan P, Srinath H, Clancy K, Parelkar S, Thompson PR. Development of a Selective Inhibitor of Protein Arginine Deiminase 2. J Med Chem. 2017 04 13; 60(7):3198-3211.
    View in: PubMed
    Score: 0.463
  3. Fuhrmann J, Subramanian V, Kojetin DJ, Thompson PR. Activity-Based Profiling Reveals a Regulatory Link between Oxidative Stress and Protein Arginine Phosphorylation. Cell Chem Biol. 2016 08 18; 23(8):967-977.
    View in: PubMed
    Score: 0.443
  4. Subramanian V, Knight JS, Parelkar S, Anguish L, Coonrod SA, Kaplan MJ, Thompson PR. Design, synthesis, and biological evaluation of tetrazole analogs of Cl-amidine as protein arginine deiminase inhibitors. J Med Chem. 2015 Feb 12; 58(3):1337-44.
    View in: PubMed
    Score: 0.397
  5. Dreyton CJ, Anderson ED, Subramanian V, Boger DL, Thompson PR. Insights into the mechanism of streptonigrin-induced protein arginine deiminase inactivation. Bioorg Med Chem. 2014 Feb 15; 22(4):1362-9.
    View in: PubMed
    Score: 0.370
  6. Jones JE, Slack JL, Fang P, Zhang X, Subramanian V, Causey CP, Coonrod SA, Guo M, Thompson PR. Synthesis and screening of a haloacetamidine containing library to identify PAD4 selective inhibitors. ACS Chem Biol. 2012 Jan 20; 7(1):160-5.
    View in: PubMed
    Score: 0.317
  7. Obianyo O, Causey CP, Jones JE, Thompson PR. Activity-based protein profiling of protein arginine methyltransferase 1. ACS Chem Biol. 2011 Oct 21; 6(10):1127-35.
    View in: PubMed
    Score: 0.314
  8. Knuckley B, Jones JE, Bachovchin DA, Slack J, Causey CP, Brown SJ, Rosen H, Cravatt BF, Thompson PR. A fluopol-ABPP HTS assay to identify PAD inhibitors. Chem Commun (Camb). 2010 Oct 14; 46(38):7175-7.
    View in: PubMed
    Score: 0.293
  9. Slack JL, Causey CP, Thompson PR. Protein arginine deiminase 4: a target for an epigenetic cancer therapy. Cell Mol Life Sci. 2011 Feb; 68(4):709-20.
    View in: PubMed
    Score: 0.292
  10. Knuckley B, Causey CP, Jones JE, Bhatia M, Dreyton CJ, Osborne TC, Takahara H, Thompson PR. Substrate specificity and kinetic studies of PADs 1, 3, and 4 identify potent and selective inhibitors of protein arginine deiminase 3. Biochemistry. 2010 Jun 15; 49(23):4852-63.
    View in: PubMed
    Score: 0.289
  11. Obianyo O, Causey CP, Osborne TC, Jones JE, Lee YH, Stallcup MR, Thompson PR. A chloroacetamidine-based inactivator of protein arginine methyltransferase 1: design, synthesis, and in vitro and in vivo evaluation. Chembiochem. 2010 Jun 14; 11(9):1219-23.
    View in: PubMed
    Score: 0.289
  12. Jones JE, Causey CP, Knuckley B, Slack-Noyes JL, Thompson PR. Protein arginine deiminase 4 (PAD4): Current understanding and future therapeutic potential. Curr Opin Drug Discov Devel. 2009 Sep; 12(5):616-27.
    View in: PubMed
    Score: 0.274
  13. Osborne T, Roska RL, Rajski SR, Thompson PR. In situ generation of a bisubstrate analogue for protein arginine methyltransferase 1. J Am Chem Soc. 2008 Apr 09; 130(14):4574-5.
    View in: PubMed
    Score: 0.247
  14. Knuckley B, Luo Y, Thompson PR. Profiling Protein Arginine Deiminase 4 (PAD4): a novel screen to identify PAD4 inhibitors. Bioorg Med Chem. 2008 Jan 15; 16(2):739-45.
    View in: PubMed
    Score: 0.240
  15. Luo Y, Arita K, Bhatia M, Knuckley B, Lee YH, Stallcup MR, Sato M, Thompson PR. Inhibitors and inactivators of protein arginine deiminase 4: functional and structural characterization. Biochemistry. 2006 Oct 03; 45(39):11727-36.
    View in: PubMed
    Score: 0.224
  16. Luo Y, Knuckley B, Lee YH, Stallcup MR, Thompson PR. A fluoroacetamidine-based inactivator of protein arginine deiminase 4: design, synthesis, and in vitro and in vivo evaluation. J Am Chem Soc. 2006 Feb 01; 128(4):1092-3.
    View in: PubMed
    Score: 0.213
  17. Mart?n Monreal MT, Rebak AS, Massarenti L, Mondal S, ?enolt L, ?dum N, Nielsen ML, Thompson PR, Nielsen CH, Damgaard D. Applicability of Small-Molecule Inhibitors in the Study of Peptidyl Arginine Deiminase 2 (PAD2) and PAD4. Front Immunol. 2021; 12:716250.
    View in: PubMed
    Score: 0.159
  18. Funabashi K, Sawata M, Nagai A, Akimoto M, Mashimo R, Takahara H, Kizawa K, Thompson PR, Ite K, Kitanishi K, Unno M. Structures of human peptidylarginine deiminase type III provide insights into substrate recognition and inhibitor design. Arch Biochem Biophys. 2021 Sep 15; 708:108911.
    View in: PubMed
    Score: 0.154
  19. Uysal-Onganer P, MacLatchy A, Mahmoud R, Kraev I, Thompson PR, Inal JM, Lange S. Peptidylarginine Deiminase Isozyme-Specific PAD2, PAD3 and PAD4 Inhibitors Differentially Modulate Extracellular Vesicle Signatures and Cell Invasion in Two Glioblastoma Multiforme Cell Lines. Int J Mol Sci. 2020 Feb 22; 21(4).
    View in: PubMed
    Score: 0.141
  20. Loring HS, Icso JD, Nemmara VV, Thompson PR. Initial Kinetic Characterization of Sterile Alpha and Toll/Interleukin Receptor Motif-Containing Protein 1. Biochemistry. 2020 03 03; 59(8):933-942.
    View in: PubMed
    Score: 0.141
  21. Mondal S, Thompson PR. Protein Arginine Deiminases (PADs): Biochemistry and Chemical Biology of Protein Citrullination. Acc Chem Res. 2019 03 19; 52(3):818-832.
    View in: PubMed
    Score: 0.132
  22. Mondal S, Parelkar SS, Nagar M, Thompson PR. Photochemical Control of Protein Arginine Deiminase (PAD) Activity. ACS Chem Biol. 2018 04 20; 13(4):1057-1065.
    View in: PubMed
    Score: 0.124
  23. Kawalkowska J, Quirke AM, Ghari F, Davis S, Subramanian V, Thompson PR, Williams RO, Fischer R, La Thangue NB, Venables PJ. Abrogation of collagen-induced arthritis by a peptidyl arginine deiminase inhibitor is associated with modulation of T cell-mediated immune responses. Sci Rep. 2016 05 23; 6:26430.
    View in: PubMed
    Score: 0.109
  24. Slade DJ, Fang P, Dreyton CJ, Zhang Y, Fuhrmann J, Rempel D, Bax BD, Coonrod SA, Lewis HD, Guo M, Gross ML, Thompson PR. Protein arginine deiminase 2 binds calcium in an ordered fashion: implications for inhibitor design. ACS Chem Biol. 2015 Apr 17; 10(4):1043-53.
    View in: PubMed
    Score: 0.099
  25. Lewis HD, Liddle J, Coote JE, Atkinson SJ, Barker MD, Bax BD, Bicker KL, Bingham RP, Campbell M, Chen YH, Chung CW, Craggs PD, Davis RP, Eberhard D, Joberty G, Lind KE, Locke K, Maller C, Martinod K, Patten C, Polyakova O, Rise CE, R?diger M, Sheppard RJ, Slade DJ, Thomas P, Thorpe J, Yao G, Drewes G, Wagner DD, Thompson PR, Prinjha RK, Wilson DM. Inhibition of PAD4 activity is sufficient to disrupt mouse and human NET formation. Nat Chem Biol. 2015 Mar; 11(3):189-91.
    View in: PubMed
    Score: 0.099
  26. Lange S, Rocha-Ferreira E, Thei L, Mawjee P, Bennett K, Thompson PR, Subramanian V, Nicholas AP, Peebles D, Hristova M, Raivich G. Peptidylarginine deiminases: novel drug targets for prevention of neuronal damage following hypoxic ischemic insult (HI) in neonates. J Neurochem. 2014 Aug; 130(4):555-62.
    View in: PubMed
    Score: 0.095
  27. Lewallen DM, Bicker KL, Madoux F, Chase P, Anguish L, Coonrod S, Hodder P, Thompson PR. A FluoPol-ABPP PAD2 high-throughput screen identifies the first calcium site inhibitor targeting the PADs. ACS Chem Biol. 2014 Apr 18; 9(4):913-21.
    View in: PubMed
    Score: 0.093
  28. Knight JS, Luo W, O'Dell AA, Yalavarthi S, Zhao W, Subramanian V, Guo C, Grenn RC, Thompson PR, Eitzman DT, Kaplan MJ. Peptidylarginine deiminase inhibition reduces vascular damage and modulates innate immune responses in murine models of atherosclerosis. Circ Res. 2014 Mar 14; 114(6):947-56.
    View in: PubMed
    Score: 0.093
  29. Fuhrmann J, Subramanian V, Thompson PR. Targeting the arginine phosphatase YwlE with a catalytic redox-based inhibitor. ACS Chem Biol. 2013 Sep 20; 8(9):2024-32.
    View in: PubMed
    Score: 0.089
  30. Foyn H, Jones JE, Lewallen D, Narawane R, Varhaug JE, Thompson PR, Arnesen T. Design, synthesis, and kinetic characterization of protein N-terminal acetyltransferase inhibitors. ACS Chem Biol. 2013; 8(6):1121-7.
    View in: PubMed
    Score: 0.088
  31. Cui X, Witalison EE, Chumanevich AP, Chumanevich AA, Poudyal D, Subramanian V, Schetter AJ, Harris CC, Thompson PR, Hofseth LJ. The induction of microRNA-16 in colon cancer cells by protein arginine deiminase inhibition causes a p53-dependent cell cycle arrest. PLoS One. 2013; 8(1):e53791.
    View in: PubMed
    Score: 0.086
  32. Obianyo O, Thompson PR. Kinetic mechanism of protein arginine methyltransferase 6 (PRMT6). J Biol Chem. 2012 Feb 17; 287(8):6062-71.
    View in: PubMed
    Score: 0.080
  33. Chumanevich AA, Causey CP, Knuckley BA, Jones JE, Poudyal D, Chumanevich AP, Davis T, Matesic LE, Thompson PR, Hofseth LJ. Suppression of colitis in mice by Cl-amidine: a novel peptidylarginine deiminase inhibitor. Am J Physiol Gastrointest Liver Physiol. 2011 Jun; 300(6):G929-38.
    View in: PubMed
    Score: 0.076
  34. Willis VC, Gizinski AM, Banda NK, Causey CP, Knuckley B, Cordova KN, Luo Y, Levitt B, Glogowska M, Chandra P, Kulik L, Robinson WH, Arend WP, Thompson PR, Holers VM. N-a-benzoyl-N5-(2-chloro-1-iminoethyl)-L-ornithine amide, a protein arginine deiminase inhibitor, reduces the severity of murine collagen-induced arthritis. J Immunol. 2011 Apr 01; 186(7):4396-404.
    View in: PubMed
    Score: 0.076
  35. Bicker KL, Obianyo O, Rust HL, Thompson PR. A combinatorial approach to characterize the substrate specificity of protein arginine methyltransferase 1. Mol Biosyst. 2011 Jan; 7(1):48-51.
    View in: PubMed
    Score: 0.073
  36. Osborne TC, Obianyo O, Zhang X, Cheng X, Thompson PR. Protein arginine methyltransferase 1: positively charged residues in substrate peptides distal to the site of methylation are important for substrate binding and catalysis. Biochemistry. 2007 Nov 20; 46(46):13370-81.
    View in: PubMed
    Score: 0.060
  37. Sagar V, Zheng W, Thompson PR, Cole PA. Bisubstrate analogue structure-activity relationships for p300 histone acetyltransferase inhibitors. Bioorg Med Chem. 2004 Jun 15; 12(12):3383-90.
    View in: PubMed
    Score: 0.048
  38. Wu Z, Deng Q, Pan B, Alam HB, Tian Y, Bhatti UF, Liu B, Mondal S, Thompson PR, Li Y. Inhibition of PAD2 Improves Survival in a Mouse Model of Lethal LPS-Induced Endotoxic Shock. Inflammation. 2020 Aug; 43(4):1436-1445.
    View in: PubMed
    Score: 0.036
  39. Horibata S, Vo TV, Subramanian V, Thompson PR, Coonrod SA. Utilization of the Soft Agar Colony Formation Assay to Identify Inhibitors of Tumorigenicity in Breast Cancer Cells. J Vis Exp. 2015 May 20; (99):e52727.
    View in: PubMed
    Score: 0.025
  40. McElwee JL, Mohanan S, Griffith OL, Breuer HC, Anguish LJ, Cherrington BD, Palmer AM, Howe LR, Subramanian V, Causey CP, Thompson PR, Gray JW, Coonrod SA. Identification of PADI2 as a potential breast cancer biomarker and therapeutic target. BMC Cancer. 2012 Oct 30; 12:500.
    View in: PubMed
    Score: 0.021
  41. Li P, Yao H, Zhang Z, Li M, Luo Y, Thompson PR, Gilmour DS, Wang Y. Regulation of p53 target gene expression by peptidylarginine deiminase 4. Mol Cell Biol. 2008 Aug; 28(15):4745-58.
    View in: PubMed
    Score: 0.016
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.